Multisystemic Inflammatory Syndrome in Children (MIS-C) With COVID-19 and Kidney Involvement: Poor Outcomes in a Case Series.
Nora S AlghamdiLujain AletaniJillian K WarejkoHasan AljefriKhalid A AlhasanMohammad A ShalabyJameela A KariPublished in: Clinical pediatrics (2024)
Multisystemic inflammatory syndrome (Mis-C) has emerged in May 2020 as a serious complication of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). A total of 6 children presented to tertiary care hospitals with Mis-C, of which 5 (83%) have died during hospitalization. All included patients presented with respiratory symptoms (ranged from mild to severe acute respiratory distress syndrome) and gastrointestinal symptoms. Most of the patients are known to have medical illnesses. Pediatric Risk of Mortality (PRISM) IV score ranged from 3 to 87. All patients developed acidosis and varying stages of acute kidney injury and electrolyte disturbances. All were treated for coagulopathy, thrombocytopenia, bacterial infections as well as antiviral medications (either ritonavir or lopinavir). Most patients had chest X-ray changes either unilateral or bilateral lung changes. Multisystemic inflammatory syndrome is a rare, yet serious complication of SARS-CoV2 infection in children. Multisystem involvement should be anticipated and promptly treated.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- respiratory syndrome coronavirus
- newly diagnosed
- chronic kidney disease
- acute respiratory distress syndrome
- acute kidney injury
- prognostic factors
- peritoneal dialysis
- oxidative stress
- young adults
- cardiovascular disease
- extracorporeal membrane oxygenation
- skeletal muscle
- cardiac surgery
- magnetic resonance
- depressive symptoms
- risk factors
- early onset
- metabolic syndrome
- computed tomography
- mass spectrometry
- patient reported outcomes
- mechanical ventilation
- insulin resistance
- ionic liquid
- sleep quality